Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…
New research explores association between hyperurecimia and gout with metabolic derangement
Role of lipids in inflammation, new insights into T cell function focus of recent research
As changes in diet and eating habits have caused obesity rates to soar, research into the metabolic syndrome suggests obesity may be a form of a low-grade inflammatory state
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.
At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.